Q32 Bio Inc QTTB.O:
Q32 BIO INC: TO DISCONTINUE RENAL BASKET TRIAL FOR ADX-097 TO CONSERVE RESOURCES
Q32 BIO INC: EVALUATE STRATEGIC OPTIONS FOR ITS TISSUE-TARGETED COMPLEMENT INHIBITOR PLATFORM
Q32 BIO INC: CASH RUNWAY EXPECTED TO EXTEND TO 2H'26
Q32 BIO INC: INITIATING OPEN-LABEL EXTENSION FROM SIGNAL-AA PART A IN 1H'25
Q32 BIO INC: SIGNAL-AA PART B REMAINS ON TRACK FOR INITIATION OF DOSING IN 1H'25, WITH TOPLINE DATA EXPECTED IN 1H'26
Source text: ID:nPn11yPfKa
Further company coverage: QTTB.O